December 23, 2021
31,254
321
231
1.77%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
8:24Now PlayingNew studies out of South Africa and the U.K. suggest the Omicron variant is less likely to cause hospitalizations -- but it can still be deadly. The FDA also authorized a new antiviral pill to treat COVID-19. CBS News' Nancy Chen reports on the latest, and then Dr. Amesh Adalja, an infectious disease expert at Johns Hopkins University Bloomberg School of Public Health, spoke with Jessi Mitchell on CBSN about the Omicron research and how some patients are experiencing different symptoms than earlier strains.
CBSN is CBS News’ 24/7 digital streaming news service featuring live, anchored coverage available for free across all platforms. Launched in November 2014, the service is a premier destination for breaking news and original storytelling from the deep bench of CBS News correspondents and reporters. CBSN features the top stories of the day as well as deep dives into key issues facing the nation and the world. CBSN has also expanded to launch local news streaming services in major markets across the country. CBSN is currently available on CBSNews.com and the CBS News app across more than 20 platforms, as well as the Paramount+ subscription service.
Subscribe to the CBS News YouTube channel
Watch CBSN live
Download the CBS News app
Follow CBS News on Instagram
Like CBS News on Facebook
Follow CBS News on Twitter
Subscribe to our newsletters
Try Paramount+ free
For video licensing inquiries, contact: licensing@veritone.com
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.